Is Medivation Too Expensive?

In this video segment, Motley Fool health care bureau chief Brenton Flynn looks at Medivation . Shares already have a lot of high expectations priced in, and the company's prostate cancer drug Xtadi sells at a 30% premium compared to competitor Zytiga from Johnson & Johnson. With similar efficacy, what will Medivation need to do to help justify the premium pricing of both its drug and stock?

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. Make sure you start 2013 with a bang and get the inside scoop on what Motley Fool superinvestor David Gardner will be buying this year. He's crushed the market in his Stock Advisor and Rule Breakers portfolios for years, and now I invite you to a personal tour of his flagship stock picking service: Supernova. Just click here now for instant access.

The article Is Medivation Too Expensive? originally appeared on Fool.com.

Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.